Long-term follow-up of patients receiving hematopoietic stem cell transplantation (HSCT) for severe scleroderma has confirmed a durable survival benefit compared to conventional treatment with cyclophosphamide. The findings, presented at the 2018 ACR/ARHP Annual Meeting in Chicago, extend the findings from the SCOT trial published earlier this year. In the SCOT trial, 75 patients with severe ...
Long term results show superiority of HSCT in severe scleroderma
By Mardi Chapman
22 Oct 2018